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To investigate the transforming potential of hepatitis C virus (HCV), HCV core protein was produced in BALB/3T3 A31-I-1
cells. The cells expressing HCV core gene cooperatively with the v-H-ras gene showed loss of contact inhibition, morpho-
logical alterations, and anchorage-independent and serum-independent growth. The cells producing HCV core protein
showed enhanced growth against stimulus of growth factor. In addition, antisense oligodeoxynucleotides against mRNA
encoding HCV core protein suppressed the growth of HCV core-producing cells. Furthermore, HCV core protein activated
mitogen-activated protein kinase and serum response element, which respond to growth stimuli. From these results, we
concluded that HCV core protein is involved in the acquisition of cell growth advantage. © 1999 Academic Press
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Hepatitis C virus (HCV) is a major causative agent of
hronic hepatitis and has been implicated in the etiology
f hepatocellular carcinoma. HCV, a member of the Fla-
iviridae family, has a positive-strand RNA genome con-
aining a large open reading frame (ORF) composed of
ver 9000 nucleotides. The precursor protein encoded in
he ORF is cleaved by viral and cellular proteases and
esults in production of structural and nonstructural pro-
eins. HCV core protein is encoded at the most 59-termi-
al region of the ORF and is produced by cleavage
etween amino acids 191 and 192 of the precursor
olyprotein by host signal peptidase (Clarke, 1997). In
ddition to the encapsidation of viral RNA, recent in vitro
tudies suggested that HCV core protein has other bio-
ogical properties. It was reported that the promoter
ctivity of c-myc, RSV LTR, SV-40 early promoter, and
P-1 is up-regulated in HCV core gene expressing cell
ines (Ray et al., 1995; Chang et al., 1998; Shrivastava et
l., 1998). It was also reported that HCV core protein
rans-suppresses some cellular promoters, i.e., p53 and
21 (Ray et al., 1997, 1998a). Though the mechanisms of
hese regulations are still unclear, it is possible that
hese properties of HCV core protein influence host cell
rowth, survival, and carcinogenesis. Recently, pro- or
nti-apoptotic properties of HCV core protein were re-
orted (Zhu et al., 1998; Ray et al., 1998b). It was also
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100hown that HCV core protein has transforming potential
n rat embryo fibroblasts with or without active ras gene
roducts (Ray et al., 1996; Chang et al., 1998), and trans-
enic mice expressing HCV core gene developed hepa-
ocellular carcinoma (Moriya et al., 1998). However, the
recise role of HCV core protein in these transformation
rocesses remains to be elucidated. Therefore, we ex-
mined the contribution of HCV core protein during the
evelopment of transformation. In this study, we found
hat HCV core protein transformed a mouse fibroblast-
erived cell line cooperatively with v-H-ras gene product.
hese transformed cells acquired a growth advantage in
erum-free medium, and antisense oligodeoxynucleo-
ides (ODN) that were designed to reduce the production
f HCV core protein suppressed the growth of these
ells. Furthermore, we found that HCV core protein en-
anced the signal transduction pathway that mediates
rowth stimuli. These results suggested that HCV core
rotein probably affects the system of cell growth.
RESULTS AND DISCUSSION
ooperative transformation of BALB/3T3 A31-I-1 cells
y HCV core protein and v-H-ras gene products
Since our preliminary studies and a previous report
howed that murine fibroblasts expressing the HCV core
ene alone did not show any transformed features, we
upposed that the transforming ability of HCV core pro-
ein is rather weak (data not shown; and Ray et al., 1996).
o detect such weak transforming activity, we coex-
ressed the HCV core gene with another oncogene,
-H-ras. In many established murine fibroblasts, the ac-
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101REGULATION OF CELL GROWTH BY HCV CORE PROTEINive ras gene product alone induces transformation.
owever, one of the subclones of BALB/3T3 cells, A31-
-1, is relatively resistant to ras-induced transformation
nd requires the presence of another oncogene, e.g.,
-myc or MTG8, for transformation (Table 1; and Kaku-
aga and Crow, 1980; Sueoka et al., 1998). BALB/3T3
31-I-1 cells were transfected with pLXSH-core191,
hich is an expression plasmid of the HCV core gene
ncoding 191 amino acids, with or without v-H-ras ex-
ression plasmid, pLXSN-ras. Several focus-forming col-
nies were obtained at 21 days posttransfection in three
ndependent experiments as shown in Table 1. The num-
er of foci was equivalent to that observed in experi-
ents performed with myc and ras genes, while trans-
ection with pLXSH-core191 alone did not show any foci
Table 1). From each cell population transfected with
CV core and ras, and with myc and ras, 20 foci were
loned for further analysis and were named Bcr and Bmr,
espectively. The production of HCV core protein in the
lones of Bcr cells was confirmed by immunoblotting
sing anti-HCV core monoclonal antibody. The HCV core
rotein was found in all these clones as a single band of
1 kDa, and no other form was detected (data not
hown).
Cloned Bcr cells showed altered morphology and a
isoriented pattern in culture dishes (Fig. 1A). We tested
hether these cells could grow in semisolid medium of
oft agar to determine their ability to undergo anchorage-
ndependent growth. All the Bcr clones (20/20) formed
olonies (Fig. 1A). We observed similar results with Bmr
lones (data not shown).
In this series of experiments, we showed that HCV
ore- and ras-transfected cells lost contact inhibition of
rowth, showed altered morphology, and acquired an-
horage-independent growth. These results suggested
hat HCV core protein transformed BALB/3T3 A31-I-1
ells cooperatively with the v-H-ras gene product.
CV core protein contributes to the acquisition of
rowth advantages of cells
The growth advantages of the cells producing HCV
ore protein were examined. First, we prepared other
TABLE 1
HCV Core Protein Transformed BALB/3T3 A31-I-1 Cells
Cooperatively with v-H-ras Gene Product
Gene constructs used
for transfection
Number of foci
Expt. I Expt. II Expt. III
LXSH core191 0 0 0
LXSH core191 1 pLXSN ras 95 112 60
LXSH 1 pLXSN ras 10 4 5
LXSH myc 1 pLXSN ras 82 144 90ALB/3T3-derived cell lines, Bmock, Bc, and Br, stably Wransfected with LXSH, LXSH-core191, and LXSN-ras, re-
pectively. Then, we compared the growth rates of Bcr
nd Bmr cells with those of Bmock, Bc, and Br cells. To
xclude the possible effect of clonal selection, we exam-
ned mixed populations consisting of 10 clones from
ach cell. Cell proliferation was measured by MTT assay
t 24-h intervals. As shown in Fig. 1B, the Bcr cells
roliferated in serum-free medium as efficiently as Bmr
ells. Bmock, Bc, and Br cells did not show any growth
nder the same conditions. We supposed that HCV core
rotein contributed to the acquisition of growth advan-
ages of BALB/3T3 cells cooperatively with active Ras.
Since Ras is activated by the stimuli of growth factors,
e examined whether HCV core protein enhances cell
rowth in growth factor-supplemented medium. Bc and
mock cells were cultured in serum-free medium sup-
lemented with 0, 0.1, and 1.0 mg/ml of epidermal growth
actor (EGF) for 72 h and proliferation of cells under each
ondition was measured by MTT assay. Bc and Bmock
ells did not proliferate in serum-free medium, and
mock cells did not respond to EGF stimuli as well as
he parental BALB/3T3 A31-I-1 clone (Fig. 1C; and Tat-
uka et al., 1989). Bc cells were sensitive to EGF stimuli
nd grew effectively (Fig. 1C). It is suggested that HCV
ore does not stimulate cell proliferation without growth
timuli, but cooperates with growth factors or their intra-
ellular downstream signals and enhances cell growth,
t least in BALB/3T3 A31-I-1 cells. Previous reports
howed that stably and inducibly expressed HCV core
rotein had no effect on cell growth (Moradpour et al.,
996; Tokushige et al., 1997). However, cell growth was
ssessed in serum-supplemented medium in these re-
orts. Bc cells did not show any growth advantages in
edium supplemented with 10% FBS (data not shown).
hey might have missed the property of HCV core protein
n the acquisition of cell growth advantage under these
onditions.
n antisense ODN against HCV core mRNA
uppressed proliferation of the HCV
ore-producing cells
To investigate whether the HCV core protein actually
ontributes to the enhancement of cell proliferation, we
ttempted to specifically reduce the production of HCV
ore protein. Previous studies showed that antisense
DN targeting of the translational initiation site of the
CV core gene reduced HCV core protein production
Hanecak et al., 1996; Wakita and Wands, 1994). Accord-
ng to these results, a phosphorothioate ODN, AS(2)5-
5, was designed complementary to the nucleotide se-
uence from 5 nucleotides upstream to 15 nucleotides
ownstream of the predicted translational initiation site
f the HCV core gene. First, we verified the suppressive
ffect of AS(2)5-15 on HCV core protein production.
hen Bcr cells were incubated with 50 mM AS(2)5-15,
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102 TSUCHIHARA ET AL.FIG. 1. Transformation of BALB/3T3 A31-I-1 cells by v-H-ras and HCV core protein. (A) Morphology on culture dishes (left column) and
nchorage-independent growth in soft agar (right column). Magnification, 340. (B) Serum-independent growth. A total of 5 3 103 transformed and
ontrol cells were cultured in the absence of serum for 72 h. Cell growth was assayed by MTT assay. “Control” was the absorbance at 570 nm at
h. The data show the means of three independent experiments. Closed triangles, BALB3T3/A31-I-1 transfected with pLXSH-core191 and pLXSN-ras
Bcr); open triangles, transfected with pLXSH-core191 (Bc); closed circles, transfected with pLXSH-myc and pLXSN-ras (Bmr); open circles, transfected
ith pLXSN-ras (Br); open squares, transfected with pLXSH (Bmock). (C) EGF-dependent growth. A total of 5 3 103 Bc and Bmock cells were cultured
n serum-free medium supplemented with 0, 0.1, and 1.0 mg/ml of EGF for 72 h and MTT assay was performed. “Control” was the absorbance at 570
m at a concentration 0 mg/ml. The data show the means of three independent experiments.
p
w
n
d
b
b
t
i
c
a
e
S
m
m
(
t
3
t
v
m
T
t
w
p
O
f
s
o
1
H
s
m
s
p
p
s
s
m
H
l
1
p
t
a
p
i
g
1
t
w
d
m
t
a
f
w
S
e
b
o
f
l
t
i
c
c
s
S
t
a
a
r
s
S
d
p
t
t
t
103REGULATION OF CELL GROWTH BY HCV CORE PROTEINroduction of HCV core protein was reduced compared
ith cells treated with the sense ODN, S(2)5-15, as a
egative control (Fig. 2A). This reduction of protein pro-
uction was likely to be specific for HCV core protein
ecause the production of actin protein was not affected
y the antisense ODN (Fig. 2A). To examine the effects of
he antisense ODN on cell proliferation, Bcr cells were
ncubated in serum-supplemented medium with various
oncentrations of AS(2)5-15 for 72 h and cell growth was
ssessed by MTT assay. AS(2)5-15 inhibited cell prolif-
ration in a dose-dependent manner. In contrast,
(2)5-15 showed no effect at concentrations up to 20
M and showed slightly reduced cell proliferation at 50
M possibly because of a nonspecific cytotoxic effect
Fig. 2B). This inhibition was specific for HCV core pro-
ein-producing cells. The proliferation of control BALB/
T3 A31-I-1 cells and Bmr cells was not affected by
reatment with 20 mM AS(2)5-15 (Fig. 2C). These obser-
ations suggested that HCV core protein contributes to
aintenance of the growth advantage of Bcr cells.
hough antisense ODN markedly reduced the produc-
ion of HCV core protein, the effect on cell proliferation
as rather small. To explain this discrepancy, one inter-
retation is that it is too short a duration for the antisense
DN treatment to alter the growth property of trans-
ormed cells. However, 72 h of treatment is sufficient for
uppression of growth of cells transformed by a viral
ncogene, as shown in a previous report (Mattia et al.,
FIG. 1—Continued997). We have another speculation. We supposed that sCV core protein cooperates with and enhances growth
timuli. Even when such an enhancer is reduced, cells
ay return to the basal level of proliferation and the
uppressive effect of anti-HCV core ODN appears to be
artial.
Following treatment with AS(2)5-15, no specific mor-
hological changes were observed in Bcr cells, but they
till showed a deformed shape (data not shown). Rever-
ion to the nontransformed morphology by 72 h of treat-
ent with antisense ODN was not likely.
CV core protein activated Erk and SRE promoter
HCV core protein was reported to activate some cel-
ular and viral promoters (Ray et al., 1995; Chang et al.,
998; Shrivastava et al., 1998). It is possible that the core
rotein activates cellular promoters involved in signal
ransduction of growth stimuli and contributes to the
cquisition of a growth advantage of HCV core protein
roducing cells. A serum response element (SRE) was
dentified beside the promoter of c-fos, and stimuli of
rowth factors activates this element (Wasylyk et al.,
998). We examined whether HCV core protein activates
he SRE. Bcr, Bc, and Bmock cells were cotransfected
ith SRE/luciferase reporter plasmid and b-galactosi-
ase reporter plasmid driven by the cytomegalovirus
inimum promoter. After transfection, cells were cul-
ured in medium supplemented with 0.5% FCS for 48 h
nd then treated with 100 ng/ml of epidermal growth
actor (EGF) for 15 min. Luciferase activity of these cells
as normalized relative to b-galactosidase activity. The
RE activity of Bc cells without EGF treatment was nearly
quivalent to that of Bmock cells. On the other hand, the
asal activity of Bcr cells was higher than that of the
ther cells. Following treatment with EGF, transcription
rom the reporter plasmid of Bc cells was induced to a
evel similar to that of Bcr cells. No such definite activa-
ion was observed in Bmock cells (Fig. 3A). These find-
ngs were consistent with the observation that the HCV
ore protein producing cells showed growth advantages
ooperatively with a growth factor or active Ras. Tran-
iently expressed HCV core gene product also activated
RE activity as well as the stable transfectant. SRE ac-
ivity in HCV core gene expressing cells is almost equiv-
lent to that of the cells that expressed constitutive
ctive MEK1, an upstream kinase of Erk (Fig. 3B). Similar
esults were observed with COS-7 cells (data not
hown). We supposed that HCV core protein enhances
RE activity cooperatively with intracellular signals
ownstream of the EGF receptor or active ras gene
roducts.
Though a previous report showed that HCV core pro-
ein activates several promoters, the mechanism of
ransactivation is still unclear (Ray et al., 1995). We at-
empted to show that HCV core protein regulates the
ignaling pathway upstream of the promoter. EGF sig-
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104 TSUCHIHARA ET AL.aling pathways act through Ras, which stimulates
ownstream kinases that ultimately activate Erk1/2.
hosphorylated and activated Erk phosphorylates ter-
ary complex factors. Phosphorylated TCF interact with
erum response factor as well as SRE to form ternary
omplexes, and then the SRE is activated (Wasylyk et al.,
998). To investigate the mechanism of SRE activation by
CV core protein, we examined the phosphorylation
attern of endogenous Erk1/2 in Bc cells. Bc and Bmock
ells were cultured in medium supplemented with 0.5%
CS for 48 h and treated with 0.1 mg/ml of EGF for 5, 10,
5, and 30 min. In Bc cells, phosphorylation of Erk1/2
as detectable within 5 min of addition of EGF, although
FIG. 2. Effects of antisense oligodeoxynucleotides. (A) Immunoblot d
r sense oligodeoxynucleotide against pLXSH-core191 at 50 mM for 72
y immunoblotting. Results of immunoblotting for actin protein are sho
ntisense oligodeoxynucleotide against the HCV core gene. Bcr cells we
r sense (open circles) oligodeoxynucleotides. Cell proliferation was
oncentration 0 mM. The data show the means of three independent e
ligodeoxynucleotides against the HCV core gene. BALB/3T3 A31-I-1 c
Bmr), or (iii) not transfected were incubated for 72 h with antisense (A
he MTT assay was performed. “Control” was the absorbance at 570 n
ndependent experiments.nly slight phosphorylation of Erk1/2 was observed in Hmock cells (Fig. 3C). These results suggested that HCV
ore protein stimulates activation of the Erk–SRE path-
ay under the control of EGF or active Ras in BALB/3T3
31-I-1 cells. We are currently engaged in further inves-
igations to clarify the mechanism. Recently, it was re-
orted that HCV core protein constitutively activates one
f the other MAPK superfamily members, JNK in MCF-7
ells stably producing core protein (Shrivastava et al.,
998). It is likely that HCV core protein has a common
echanism that activates MAPK family kinases.
Liver is persistently regenerating following hepatic in-
ury and growth factors stimulate this liver regeneration
n hepatitis (Masuhara et al., 1996). It is possible that
ation of HCV core protein levels in Bcr cells exposed to the antisense
cell lysates were electrophoresed and HCV core protein was detected
internal controls. (B) Dose-dependent inhibition of cell proliferation by
bated for 72 h with various concentrations of antisense (closed circles)
sed by MTT assay. “Control” was the absorbance at 570 nm at a
ents. (C) HCV core-specific inhibition of cell proliferation by antisense
nsfected with (i) HCV core and v-H-ras (Bcr) or (ii) c-myc and v-H-ras
5) or sense (S(2)5-15) oligodeoxynucleotide at 20 mM (see text), and
ligodeoxynucleotide-free samples. The data show the means of threeetermin
h. Total
wn as
re incu
asses
xperim
ells tra
S(2)5-1
m of oCV core protein in regenerating hepatocytes enhances
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105REGULATION OF CELL GROWTH BY HCV CORE PROTEINrowth stimuli and repeated hepatocyte proliferation
ay cause a disorder of genes in hepatocytes, thus
ausing hepatocellular carcinoma. In addition, we
FIG. 3. Activation of Erk-SRE signaling pathway by HCV core protein
lasmid. Cells were cultured in serum-reduced medium (0.5% FBS) fo
ormalized relative to cotransfected b-galactosidase activity. (B) BALB
xpressing plasmid, constitutive active MEK1 expressing plasmid as a
easured. (C) Bc and Bmock cells were treated with 0.1 mg/ml of EGF
ntibody.howed that reduction of HCV core protein production iancels the growth advantage. These observations will
elp to elucidate the viral pathogenesis and to develop
reatment regimens for hepatocellular carcinoma follow-
, Bcr, and Bmock cells were transfected with SRE/luciferase reporter
(open bar) and stimulated by EGF (solid bar). Luciferase activity was
31-I-1 cells were cotransfected with reporter plasmid and HCV core
e control, or empty vector. After EGF treatment, luciferase activity was
30 min and activated Erk1/2 was detected using anti-phospho-MAPK. (A) Bc
r 48 h
/3T3 A
positiv
for 0–ng HCV infection.
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106 TSUCHIHARA ET AL.MATERIALS AND METHODS
ell line and plasmids
BALB/3T3 A31-I-1 cells (JCRB0601, provided by Dr.
iyoshi Sasaki, Hatano Research Institute, Food and
rug Safety Center, Kanagawa, Japan) were maintained
n minimal essential medium (MEM, Nissui, Tokyo, Ja-
an) supplemented with 10% fetal calf serum. Plasmid
LXSH-core191 was constructed by inserting the PCR
roduct encoding the entire 191 amino acids of the HCV
ore gene into the retrovirus vector pLXSH (provided by
r. Dusty Miller, Fred Hutchinson Cancer Research Cen-
er, Seattle, WA). Plasmid pC980 containing the N-termi-
al 980-amino-acid coding region of HCV-J cDNA was
sed as a template for PCR (Hijikata et al., 1991). The
-myc fragment (obtained from Japan Cancer Research
esources Bank, YG-CO053) was also cloned into
LXSH and designated pLXSH-myc. The constitutively
ctive ras gene-expressing plasmid pLXSN-ras was con-
tructed by inserting the v-H-ras fragment from the Har-
ey murine sarcoma virus genome into the retroviral
ector pLXSN (Ellis et al., 1980).
n vitro transformation assay
BALB/3T3 cells (2 3 105 cells per 100-mm diameter
late) were transfected with 1 mg of pLXSH-core191 gene
ith or without 1 mg of pLXSN-ras using Lipofectamine
lus reagent (Life Technologies, Grand Island, NY) ac-
ording to the manufacturer’s protocol. The cells were
aintained in MEM supplemented with 5% fetal calf
erum and were fed every 4 days. Transformed foci were
ounted at 21 days posttransfection. pLXSH-myc and
LXSN-ras were used in cotransfection experiments as
ositive controls. From each set of transfections, 20 foci
ere picked and subcloned. Anchorage-independent
rowth was assessed by soft agar assay. Briefly, 3 ml of
ase medium containing 5% fetal calf medium with 1%
EAPLAQUE agarose (FMC, ME) in 60-mm culture
ishes was used. Cells (103 cells/dish) were seeded in 4
l of medium containing 5% fetal calf serum with 0.33%
gar and layered onto the base. Colonies were observed
fter 10 days. Cell growth was measured by MTT assay
ith a CellTiter 96 Non-radioactive Cell Proliferation As-
ay kit (Promega, Madison, WI) according to the manu-
acturer’s protocol.
ntisense oligodeoxynucleotides
Phosphorothioate oligonucleotides were purchased
rom GlinerJapan Corp. (Tokyo, Japan). AS(2)5-15 (AG-
ATTTGTGCTCATGATGC) targeted the initiation site of
he HCV core gene in pLXSH-core191. S(2)5-15 (GCAT-
ATGAGCACAAATCCT) was complementary to AS(2)5-
5. These oligonucleotides were added to the culture
edium at various concentrations and subsequent as-ays were performed.mmune detection of HCV core protein
The protein samples were separated by 12.5% SDS–
AGE. The electrophoresed proteins were transferred
nto PVDF membranes. Membranes were incubated
ith blocking buffer (5% dried milk, 5% fetal bovine se-
um, 0.05% Tween 20, phosphate-buffered saline) and
hen incubated with anti-HCV core monoclonal antibody
515S, provided by Dr. Michinori Kohara, The Metropoli-
an Institute of Medical Science, Tokyo, Japan) at 1 mg/ml
n blocking buffer for 60 min. Membranes were subse-
uently treated with horseradish peroxidase-conjugated
nti-mouse antibody at a 1:3000 dilution for 45 min.
rotein binding was detected with Western Blot Chemi-
uminescence Reagent Plus (NEN Life Science Products,
oston, MA).
RE reporter enzyme assay
SRE activity was assayed with the PathDetect Cis-
eporting System (Stratagene, San Diego, CA). Trans-
ected cells were maintained in MEM supplemented with
.5% fetal bovine serum for 48 h. Then, 100 ng/ml of
pidermal growth factor (Toyobo, Osaka, Japan) was
dded to the medium and cells were incubated at 37°C
or 15 min. Luciferase activity was measured with Lucif-
rase Assay System (Promega) and Lumat LB9507
EG&G Berthold, Bad Wildbad, Germany) according to
he manufacturer’s protocol.
mmune detection of phosphorylated Erk
The protein samples were separated by 10% SDS–
AGE and transferred onto PVDF membranes. Mem-
ranes were blocked and incubated with rabbit anti-
hospho-p42/44 MAP kinase polyclonal antibody or rab-
it anti-MAPK antibody (NEB, Boverly, MA) at a 1:1000
ilution in blocking buffer for 60 min. Membranes were
ubsequently treated with HRP-conjugated anti-rabbit
ntibody at a 1:1000 dilution for 45 min.
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